Skip to main content
Top
Published in: Rheumatology International 12/2016

01-12-2016 | Observational Research

Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease

Authors: Julie Obert, Olivia Freynet, Hilario Nunes, Pierre-Yves Brillet, Makoto Miyara, Robin Dhote, Dominique Valeyre, Jean-Marc Naccache

Published in: Rheumatology International | Issue 12/2016

Login to get access

Abstract

Interstitial lung disease (ILD) is a common form of extramuscular involvement in patients with polymyositis/dermatomyositis and is associated with poor prognosis. This study was designed to describe the long-term outcome of myositis-associated ILD. This retrospective observational study was conducted in 48 consecutive patients. Two groups defined according to outcome were compared to determine prognostic factors: a “severe” group (vital capacity [VC] < 50 % or carbon monoxide transfer factor [TLCO] < 35 % or death or lung transplantation) and a “nonsevere” group (other patients). The study population comprised 31 women and 17 men with a median age of 49.5 ± 13.6 years. Mean PFT results at the onset of ILD were 56.9 ± 23.1 % pred. for VC and 42.1 ± 16.6 % pred. for TLCO. Median (range) follow-up was 65 (2–204) months. Three patients (6.4 %) died. At last follow-up, 19 patients were classified in the “severe” group and 27 patients were classified in the “nonsevere” group. Two patients lost to follow-up after less than 12 months were excluded from this analysis. Multivariate analysis identified two independent prognostic factors: VC at onset of ILD [OR 0.95 (95 % CI 0.90–0.99)] and myopathic changes on electromyography [OR 5.76 (95 % CI 1.10–30.3)]. Patients treated in our pulmonology department for myositis-associated ILD had severe initial PFT results but a low mortality rate. Independent prognostic factors at presentation were initial VC and myopathic changes on electromyography. This study highlights the need for studies focusing on the correlation between muscle and lung pathogenic mechanisms.
Literature
3.
go back to reference Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84(4):231–249CrossRefPubMed Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84(4):231–249CrossRefPubMed
5.
go back to reference Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70(6):360–374CrossRefPubMed Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70(6):360–374CrossRefPubMed
6.
go back to reference Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK et al (1990) Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77(282):1019–1038CrossRefPubMed Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK et al (1990) Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77(282):1019–1038CrossRefPubMed
7.
go back to reference Dickey BF, Myers AR (1984) Pulmonary disease in polymyositis/dermatomyositis. Sem Arthritis Rheum 14(1):60–76CrossRef Dickey BF, Myers AR (1984) Pulmonary disease in polymyositis/dermatomyositis. Sem Arthritis Rheum 14(1):60–76CrossRef
8.
go back to reference Hepper NG, Ferguson RH, Howard FM Jr (1964) Three types of pulmonary involvement in polymyositis. Med Clin N Am 48:1031–1042CrossRefPubMed Hepper NG, Ferguson RH, Howard FM Jr (1964) Three types of pulmonary involvement in polymyositis. Med Clin N Am 48:1031–1042CrossRefPubMed
11.
go back to reference Arakawa H, Yamada H, Kurihara Y, Nakajima Y, Takeda A, Fukushima Y et al (2003) Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 123(4):1096–1103CrossRefPubMed Arakawa H, Yamada H, Kurihara Y, Nakajima Y, Takeda A, Fukushima Y et al (2003) Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 123(4):1096–1103CrossRefPubMed
12.
go back to reference Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22(2):245–250CrossRefPubMed Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22(2):245–250CrossRefPubMed
13.
go back to reference Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT et al (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 107(6):890–896. doi:10.1016/j.rmed.2013.02.015 CrossRefPubMed Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT et al (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 107(6):890–896. doi:10.​1016/​j.​rmed.​2013.​02.​015 CrossRefPubMed
15.
go back to reference Shinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M, Kawakami M et al (1997) Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 36(7):519–523CrossRefPubMed Shinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M, Kawakami M et al (1997) Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 36(7):519–523CrossRefPubMed
16.
go back to reference Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51(9):1563–1570. doi:10.1093/rheumatology/kes102 CrossRefPubMed Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51(9):1563–1570. doi:10.​1093/​rheumatology/​kes102 CrossRefPubMed
17.
go back to reference Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63(11):3439–3447. doi:10.1002/art.30513 CrossRefPubMed Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63(11):3439–3447. doi:10.​1002/​art.​30513 CrossRefPubMed
18.
go back to reference Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, Christopher-Stine L, Danoff S (2016) Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194(5):733–737. doi:10.1007/s00408-016-9896 CrossRefPubMed Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, Christopher-Stine L, Danoff S (2016) Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194(5):733–737. doi:10.​1007/​s00408-016-9896 CrossRefPubMed
19.
20.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. doi:10.1164/rccm.2009-040GL CrossRefPubMed Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. doi:10.​1164/​rccm.​2009-040GL CrossRefPubMed
22.
go back to reference Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748. doi:10.1164/rccm.201308-1483ST CrossRefPubMed Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748. doi:10.​1164/​rccm.​201308-1483ST CrossRefPubMed
23.
go back to reference Kambouchner M, Levy P, Nicholson AG, Schubel K, Magois E, Feuillet S et al (2014) Prognostic relevance of histological variants in nonspecific interstitial pneumonia. Histopathology 65:549–560. doi:10.1111/his.12415 CrossRefPubMed Kambouchner M, Levy P, Nicholson AG, Schubel K, Magois E, Feuillet S et al (2014) Prognostic relevance of histological variants in nonspecific interstitial pneumonia. Histopathology 65:549–560. doi:10.​1111/​his.​12415 CrossRefPubMed
24.
27.
Metadata
Title
Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease
Authors
Julie Obert
Olivia Freynet
Hilario Nunes
Pierre-Yves Brillet
Makoto Miyara
Robin Dhote
Dominique Valeyre
Jean-Marc Naccache
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3571-7

Other articles of this Issue 12/2016

Rheumatology International 12/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.